膵がんによる筋萎縮を抑える新たな標的を発見(University of Houston Researchers Identify New Target to Counteract Muscle Wasting in Pancreatic Cancer)

ad

2025-12-16 ヒューストン大学(UH)

ヒューストン大学薬学部の研究チームは、膵臓がんに伴う筋萎縮(がん性カヘキシア)を抑制する新たな治療標的を同定した。がん性カヘキシアは膵臓がん患者の60~85%に発症し、骨格筋量が進行性に失われる重篤な合併症である。研究では、細胞内小器官である小胞体に関わるIRE1α/XBP1シグナル経路が筋萎縮の主要因であることを示した。マウスモデルにおいて、骨格筋特異的にXBP1転写因子を欠失させると、膵腫瘍による筋量低下が有意に抑制された。IRE1α/XBP1経路は、タンパク質分解の亢進や合成低下など、筋萎縮を引き起こす複数の分子機構を制御していることも明らかになった。本成果は、膵臓がん患者の生活の質改善につながる新たな治療戦略の基盤を提供するとともに、他のがん性カヘキシアへの応用可能性も示唆している。研究成果はEMBO Molecular Medicineに掲載された。

<関連情報>

標準的なERストレスIRE1α/XBP1経路は膵臓癌悪液質中の骨格筋消耗を媒介する The canonical ER stress IRE1α/XBP1 pathway mediates skeletal muscle wasting during pancreatic cancer cachexia

Aniket S Joshi,Meiricris Tomaz da Silva,Anh Tuan Vuong,Bowen Xu,Ravi K Singh & Ashok Kumar
EMBO Molecular Medicine  Published:17 November 2025
DOI:https://doi.org/10.1038/s44321-025-00337-w

Abstract

Cancer cachexia is a debilitating syndrome characterized by the progressive loss of skeletal muscle mass with or without fat loss. Recent studies have implicated dysregulation of the endoplasmic reticulum (ER) stress-induced unfolded protein response (UPR) pathways in skeletal muscle under various conditions, including cancer. In this study, we demonstrate that the IRE1α/XBP1 branch of the UPR promotes activation of the ubiquitin–proteasome system, autophagy, JAK-STAT3 signaling, and fatty acid metabolism in the skeletal muscle of the KPC mouse model of pancreatic cancer cachexia. Moreover, we show that the IRE1α/XBP1 pathway is a key contributor to muscle wasting. Skeletal muscle-specific deletion of the XBP1 transcription factor significantly attenuates tumor-induced muscle atrophy. Mechanistically, transcriptionally active XBP1 binds to the promoter regions of genes such as Map1lc3b, Fbxo32, and Il6, which encode proteins known to drive muscle proteolysis. Pharmacological inhibition of IRE1α using 4µ8C in KPC tumor-bearing mice attenuates cachexia-associated molecular changes and improves muscle mass and strength. Collectively, our findings suggest that targeting IRE1α/XBP1 pathway may offer a therapeutic strategy to counteract muscle wasting during pancreatic cancer-induced cachexia.

Synopsis

膵がんによる筋萎縮を抑える新たな標的を発見(University of Houston Researchers Identify New Target to Counteract Muscle Wasting in Pancreatic Cancer)
The study identifies the IRE1α/XBP1 arm of the ER stress-induced unfolded protein response as a key driver of skeletal muscle wasting and demonstrates that its genetic or pharmacological inhibition can attenuate the loss of skeletal muscle mass and function during pancreatic cancer-induced cachexia.

  • The IRE1α/XBP1 arm of the unfolded protein response is activated in skeletal muscle during pancreatic cancer cachexia.
  • Targeted deletion of XBP1 in mice counteracts the loss of skeletal muscle mass in response to tumor growth.
  • XBP1 transcription factor augments the gene expression of key molecules involved in the regulation of proteolytic systems, STAT3 signaling, and fatty acid metabolism in skeletal muscle of tumor-bearing mice.
  • Pharmacological inhibition of the IRE1α/XBP1 axis attenuates skeletal muscle wasting in response to pancreatic tumor growth.
医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました